Tag: LP1R
ACS: 2020 to 2024 Saw Jump in Use of GLP-1 Receptor Agonists Before Metabolic,...
Even higher use seen in patients without type 2 diabetes
Metabolic Surgery Has Greater Long-Term Benefits Than GLP-1 Receptor Agonists
Findings seen for long-term outcomes among adult patients with diabetes and obesity
GLP-1 Receptor Agonists Tied to Reduced Mortality in Patients With Psoriasis
Risk reductions stronger in those with psoriasis versus those with obesity or type 2 diabetes without psoriasis
Oral Semaglutide Effective for Weight Loss in Overweight or Obesity
Estimated mean change in body weight from baseline to week 64 was −13.6 and −2.2 percent with oral semaglutide and placebo, respectively
Oral Orforglipron Yields Greater Weight Reductions Than Placebo
Significant mean change in body weight from baseline to week 72 seen with various dosages of orforglipron compared with placebo among adults with obesity
GLP-1 Receptor Agonists Improve Glycemic, Weight Outcomes in Children With T2D
Glycemic, weight, cardiometabolic outcomes improved for children and teens with obesity, prediabetes, or T2D
GLP-1 RAs Cost-Effective Versus Usual Care for Knee OA, Obesity
Tirzepatide offers more favorable return on investment, but greater benefits seen at lower costs for Roux-en-Y gastric bypass
WHO Updates List of Essential Medicines to Include GLP-1s
PD-1/PD-L1 immunotherapies for several metastatic cancers also made the list of essential drugs
14 Percent of U.S. Adults Initiate GLP-1 Receptor Agonist After Bariatric Surgery
Women, those undergoing sleeve gastrectomy, those with type 2 diabetes more likely to initiate GLP-1 RAs
GLP-1 Receptor Agonists Linked to Reduced Risk for Developing Uveitis
GLP-1 RAs linked to lower risk among those with type 2 diabetes and without diabetes; greater protection seen versus metformin, insulin
